Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Lasa Supergenerics's Revenue for the
three
months ended in Mar. 2026 was ₹-1.3 Mil. Lasa Supergenerics's average Accounts Receivable for the
three
months ended in Mar. 2026 was ₹0.4 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Lasa Supergenerics Receivables Turnover Related Terms
Lasa Supergenerics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Lasa Supergenerics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LASA vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lasa Supergenerics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lasa Supergenerics Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lasa Supergenerics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Lasa Supergenerics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lasa Supergenerics (NSE:LASA) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lasa Supergenerics and its competitors. According to the industry distribution chart, Lasa Supergenerics ranks #34 out of 950 companies in the Drug Manufacturers industry, placing it in the top 3.6%.
Is Lasa Supergenerics' Receivables Turnover too high?
Lasa Supergenerics' current Receivables Turnover is 0.00. Based on the distribution chart, Lasa Supergenerics ranks #34 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lasa Supergenerics has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lasa Supergenerics' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lasa Supergenerics ranks #34 out of 950 companies for Receivables Turnover. This places Lasa Supergenerics in the top 4% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lasa Supergenerics and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lasa Supergenerics's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lasa Supergenerics stock overvalued right now?
Based on GuruFocus' analysis, Lasa Supergenerics (NSE:LASA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹4.28, compared to a current price of ₹6.94 — trading 62.1% above its estimated fair value. The current Receivables Turnover is 0.00. Lasa Supergenerics' overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Lasa Supergenerics (NSE:LASA), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lasa Supergenerics (NSE:LASA) Overvalued in 2026?
Based on GuruFocus' analysis, Lasa Supergenerics stock appears to be overvalued.
The current stock price of ₹6.94 is trading 62.1% above its estimated GF Value™ of ₹4.28.
GuruFocus considers Lasa Supergenerics to be Significantly Overvalued.
Key valuation signals for NSE:LASA:
Receivables Turnover: 0.00
GF Value™: ₹4.28 vs. price of ₹6.94 (62.1% above fair value)
No single metric tells the full story. See the NSE:LASA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lasa Supergenerics Ltd is engaged in the research, manufacturing, trading, producing, processing, preparing, and treating chemicals, API, pharmaceuticals, drugs, and related products. The company specializes in catalyst chemistry and manufactures anthelmintic and veterinary API products. Its product range includes API products, other API products, animal feed ingredients, and reagents for therapeutic use.
43GF Score
Get the complete analysis for NSE:LASA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LASA has been successfully added to your 
